Development of vaccines against influenza H5

Lancet Infectious Diseases

Volumn 6, Issue 8, 2006, Pages 458-460

  Stephenson, Iain ^a   Gust, Ian ^b,c   Pervikov, Yuri ^d   Kieny, Marie Paule ^d  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A; LETTER; PRIORITY JOURNAL; SEROCONVERSION; VACCINE PRODUCTION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 33746266740     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70528-X     Document Type: Letter

References (10)

1. WHO. Avian influenza. http://www.who.int/csr/disease/avian_influenza/en (accessed June 22, 2006)
2. WHO Global Influenza Program Surveillance Network. Evolution of avian influenza viruses in Asia. Emerg Infect Dis 11 (2005) 1515-1521
3. Stephenson I., Gust I., Kieny M., and Pervikov Y. Development and evaluation of pandemic influenza vaccines. Lancet Infect Dis 6 (2006) 71-72
4. Webby R., Perez D., Coleman J., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 (2004) 1009-1103
5. Treanor J., Campbell J., Zangwill K., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1345-1351
6. Bresson J., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
7. Stephenson I., Nicholson K., Wood J., Zambon M., and Katz J. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4 (2004) 499-509
8. Lipatov A., Webby R., Govorkova E., Krauss S., and Webster R. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191 (2005) 1216-1220
9. Hoffmann E., Lipatov A., Webby R., Govorkova E., and Webster R. Role of haemagglutinin amino acids in the immunogenicity and protection of influenza virus vaccines. Proc Natl Acad Sci USA 102 (2005) 12915-12920
10. Stephenson I., Bugarini R., Nicholson K., et al. Cross-reactivity to highly pathogenic avian influenza viruses after vaccination with MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 (2005) 1210-1215